VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 3, 2010, Pages 647-658

  Sinha, Sutapa ^a   Cao, Ying ^a   Dutta, Shamit ^a   Wang, Enfeng ^a   Mukhopadhyay, Debabrata ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Mice model; Renal cell carcinoma; Vinorelbine and 2C3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; DRUG DERIVATIVE; NAVELBINE; NEUTRALIZING ANTIBODY; VASCULOTROPIN; VINBLASTINE;

ANIMAL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; VASCULAR ENDOTHELIAL GROWTH FACTORS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 77953490722     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00578.x     Document Type: Article

References (53)

1. Flanigan RC, Campbell SC, Clark JI. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003, 4:385-90.
2. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000, 27:187-93.
3. Motzer RJ, Bacik J, Schwartz LH. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004, 22:454-63.
4. Chow WH, Devesa SS, Warren JL. Rising incidence of renal cell cancer in the United States. JAMA. 1999, 281:1628-31.
5. Bambust I, Van Aelst F, Joosens E. A Belgian registry of interleukin-2 administration for treatment of metastatic renal cell cancer and confrontation with literature data. Acta Clin Belg. 2007, 62:223-9.
6. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004, 4:1081-96.
7. Cohen T, Nahari D, Cerem LW. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996, 271:736-41.
8. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron. 1997, 77:212-8.
9. Claffey KP, Abrams K, Shih SC. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab Invest. 2001, 81:61-75.
10. Pertovaara L, Kaipainen A, Mustonen T. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994, 269:6271-4.
11. Ryuto M, Ono M, Izumi H. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem. 1996, 271:28220-8.
12. Wang TH, Horng SG, Chang CL. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002, 87:3300-8.
13. Forsythe JA, Jiang BH, Iyer NV. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16:4604-13.
14. Levy AP, Levy NS, Wegner S. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem. 1995, 270:13333-40.
15. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 2001, 61:6952-7.
16. Rini BI. Sunitinib. Expert Opin Pharmacother. 2007, 8:2359-69.
17. Dutcher JP. Mammalian target of rapamycin inhibition. Clin Cancer Res. 2004, 10:6382S-7S.
18. Rowinsky ER, Donehower RC. Antimicrotubule agents. 1997, Volume 1:468-72. Philadelphia, PA, Lippincott-Reven, pp
19. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991, 51:2212-22.
20. Johnson SA, Harper P, Hortobagyi GN. Vinorelbine: an overview. Cancer Treat Rev. 1996, 22:127-42.
21. Depenbrock H, Shirvani A, Rastetter J. Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Invest New Drugs. 1995, 13:187-93.
22. Brekken RA, Huang X, King SW. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998, 58:1952-9.
23. Bonfil RD, Russo DM, Schmilovich AJ. Exposure to vinorelbine inhibits in vitro proliferation and invasiveness of transitional cell bladder carcinoma. J Urol. 1996, 156:517-21.
24. Ngan VK, Bellman K, Hill BT. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001, 60:225-32.
25. Photiou A, Sheikh MN, Bafaloukos D. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol. 1992, 118:249-54.
26. Ngan VK, Bellman K, Panda D. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000, 60:5045-51.
27. Davidson EJ, Morris LS, Scott IS. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer. 2003, 88:257-62.
28. Pagano M, Pepperkok R, Verde F. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992, 11:961-71.
29. King RW, Jackson PK, Kirschner MW. Mitosis in transition. Cell. 1994, 79:563-71.
30. Thant AA, Nawa A, Kikkawa F. Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells. Clin Exp Metastasis. 2000, 18:423-8.
31. Toh HC, Sun L, Koh CH. Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. Leuk Lymphoma. 1998, 31:195-208.
32. Beck SD, Patel MI, Snyder ME. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004, 11:71-7.
33. El-Galley R, Keane TE, Sun C. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003, 21:49-57.
34. Goldstein D, Ackland SP, Bell DR. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs. 2006, 24:429-34.
35. Motzer RJ, Lyn P, Fischer P. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol. 1995, 13:1958-65.
36. Palmeri S, Gebbia V, Russo A. Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma. Tumori. 1990, 76:64-5.
37. Goa KL, Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging. 1994, 5:200-34.
38. Mir O, Berveiller P, Ropert S. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 2007, 19:607-13.
39. Catania C, Medici M, Magni E. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol. 2007, 18:1969-75.
40. Guida M, Lorusso V, De Lana M. Subcutaneous rIL-2 plus vinorelbine(VNB) and gemcitabin (GEM) in metastatic renal cell carcinoma. Annu Meet Am Soc Clin Oncol (ASCO) 2002, 21:2420.
41. Takahashi T, Caviness VS. PCNA-binding to DNA at the G1/S transition in proliferating cells of the developing cerebral wall. J Neurocytol. 1993, 22:1096-102.
42. Longo R, D'Andrea MR, Sarmiento R. Integrated therapy of kidney cancer. Ann Oncol. 2007, 18:vi141-8.
43. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005, 23:1028-43.
44. Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003, 349:427-34.
45. Hainsworth JD, Sosman JA, Spigel DR. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005, 23:7889-96.
46. Thomsson DS, Greco FA, Spigel DR. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial. J Clin Oncol. 2006, 24:240s.
47. Holloway SE, Beck AW, Shivakumar L. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surg Oncol. 2006, 13:1145-55.
48. Stephan S, Datta K, Wang E. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res. 2004, 10:6993-7000.
49. Zhang W, Ran S, Sambade M. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis. 2002, 5:35-44.
50. Forest V, Peoc'h M, Campos L. Effects of cryotherapy or chemotherapy on apoptosis in a non-small-cell lung cancer xenografted into SCID mice. Cryobiology. 2005, 50:29-37.
51. Kolberg HC, Villena-Heinsen C, Deml MM. Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice. Eur J Gynaecol Oncol. 2005, 26:398-402.
52. Stickle NH, Cheng LS, Watson IR. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res. 2005, 578:23-32.
53. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005, 65:9021-8.